Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy

Department of Clinical and Experimental Medicine, Section of Internal Medicine and Oncological Sciences, Centre for the Study of Rheumatic Diseases, University of Perugia, Italy.
Rheumatology (Impact Factor: 4.48). 01/2000; 38(12):1282-4.
Source: PubMed


To evaluate whether serum levels of the soluble form of CD30 (sCD30) correlate with disease activity in early rheumatoid arthritis (RA) and may have prognostic value in predicting the response to disease-modifying anti-rheumatic drugs (DMARDs).
The levels of sCD30 and C-reactive protein (CRP) were measured in the serum of 14 untreated subjects with early RA, before and during treatment with hydroxychloroquine, for a follow-up period of 8 months. At the end of the study, patients were also evaluated for their response to DMARDs.
An inverse correlation between sCD30 and CRP serum values was demonstrated at baseline, but not during the follow-up. Patients who responded to DMARD therapy had higher sCD30 basal levels than non-responders.
The evaluation of sCD30 serum levels in early RA may reflect the attempt by CD30+ T cells to downmodulate inflammation and may be a useful marker to predict a good response to DMARDs.

6 Reads
  • Source
    • "It has been shown that the extramembranous region of CD30 is cleaved by a metalloprotease and released into the bloodstream after cell activation as a soluble protein (sCD30), and recent studies have explored the roles of the protein in various diseases, including malignant disorders, infectious diseases [4], rejection after organic transplantation [9], and autoimmune diseases [10] [11] [12] [13] [14]. Moreover, it has been proposed that sCD30 may serve as a diagnostic marker in various autoimmune disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Soluble CD30 (sCD30), a transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily, has been shown to be associated with various pathological conditions. This study was designed to measure the levels of serum sCD30 in patients with ankylosing spondylitis (AS) and to evaluate the relationships between serum sCD30 levels and other disease severity-related indexes, including bath ankylosing spondylitis disease activity index (BASDAI), ankylosing spondylitis disease activity score (ASDAS), and bath ankylosing spondylitis functional index (BASFI). Our results demonstrated significantly elevated sCD30 levels in AS patients compared to healthy controls (HCs) with mean values of 32.0 ± 12.2 and 24.9 ± 8.0 ng/mL, respectively (P (**) = 0.007), suggesting a potential role of sCD30 in the pathogenesis of AS. However, no significant correlations of sCD30 with BASDAI, ASDAS, or BASFI were detected in our study (P > 0.05). Therefore, sCD30 cannot be used as a reliable marker for reflecting disease activity and functional ability of AS patients.
    Full-text · Article · Aug 2015
  • Source
    • "The increase of the expression of membrane CD30 during an autoimmune inflammation is based on a mechanism of involving the inflammatory cells in an antigen response reaction. So the patients with early rheumatoid arthritis have an increase of the CD30 surface receptor from 0.73% ± 0.76% up to 3.68% ± 0.60% registered for the donors [29] [30], however in the presence of the extract this figure decreases to 2.90% ± 0.25%. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Materials and Methods: lymphocytes of 10 pa-tients having early rheumatoid arthritis (RA) (the duration of the illness was 3 -6 months) with a marked exudational process in joints were ex-amined. The content of lymphocytes expressing the mIgM, mIgG antigens was determined. Results: the "Taban-Arshan" extract corrects the changes of the immune system character-ized by the evident activation of the B-cell part of the immune system and normalizes immune parameters of the lymphocytes taken from the patients with autoimmune diseases (early rheumatoid arthritis). The immunocorrective effect of the "Taban-Arshan" extract is related to its ability to suppress the lymphocyte increased activation by normalizing expression of the main activation antigens (CD23, CD25, CD71, HLA-DR, CD54).
    Preview · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: High serum levels of soluble CD30 (sCD30) have been reported to better predict the response to second line therapy in rheumatoid arthritis (RA). It is believed that sCD30 is released by CD30+ T cells present in the RA synovium. However, both the mechanism of recruitment to the joint and the functional role of this T cell subset in the pathogenesis of the disease remain unknown. This study confirmed higher levels of sCD30 in the serum and synovial fluid (SF) of RA patients compared with normal controls. However, analysis of mRNA and cell surface CD30 expression showed that CD30+ T cells are detectable in the SF, but not in the synovial membrane. In contrast, T cells expressing the CD30 transcript, but not the surface molecule, were found in the peripheral blood of both RA and normal controls. CD30 surface expression was up-regulated by adhesion and migration through endothelium in vitro and in a delayed-type hypersensitivity model in vivo. Although the great majority of fresh or cloned CD30+ T cells from SF produced both IFN-γ and IL-4, CD30 expression strictly correlated with IL-4 synthesis in synovial T cell clones. In addition, CD30+ T cell clones also produced high amounts of the anti-inflammatory cytokine IL-10. On this basis, we would like to propose that synovial CD30+ cells may play a role in the control of the inflammatory response. Serum sCD30 may reflect such cell activity and, therefore, explain the previously demonstrated correlation between high sCD30 serum levels and positive response to therapy.
    Full-text · Article · Apr 2000 · The Journal of Immunology
Show more